Elevar Gets Third CRL for Rivoceranib in HCC

Update September 24, 2026: The lirafugratinib PDUFA referenced below as “pending” has resolved — approved September 23 as Lyrfigtu for FGFR2+ cholangiocarcinoma, Elevar’s first US approval. The rivoceranib CRL analysis remains unchanged.

The FDA issued a third Complete Response Letter to Elevar Therapeutics on July 10, 2026, blocking approval of rivoceranib plus camrelizumab as first-line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). The rejection cited deficiencies from a cGMP inspection of a manufacturing site. No concerns were raised about clinical efficacy or safety.

Elevar is a majority-owned subsidiary of HLB Co., Ltd., which trades on the Korean exchange. The combination is not US-listed, so there is no direct stock ticker to track. The drug is already approved in China for first-line HCC under the brand names Aitan (rivoceranib) and AiRuiKa (camrelizumab), both developed by Hengrui Pharma.

What the data showed

The NDA was based on the global Phase 3 CARES-310 trial (NCT03764293), in which the combination achieved a median overall survival of 23.8 months versus 15.2 months for sorafenib. That is the longest overall survival reported to date among first-line HCC regimens. Treatment-related adverse events leading to discontinuation occurred in 17.6% of patients for camrelizumab and 16.9% for rivoceranib, with 4.4% discontinuing both. Grade 3 or higher toxicities were dominated by hypertension and transaminase elevations.

Rivoceranib is an oral tyrosine kinase inhibitor targeting VEGFR, a primary pathway for tumor angiogenesis (the formation of new blood vessels that feed tumors). Camrelizumab is a humanized anti-PD-1 antibody that releases the immune system’s brakes on T-cells, the same checkpoint inhibitor class as Merck’s Keytruda and Bristol Myers Squibb’s Opdivo. The combination attacks the tumor through two mechanisms: cutting its blood supply while simultaneously reactivating immune recognition. Camrelizumab has been studied in over 5,000 patients and is approved for eight indications in China.

The science worked. The factory did not pass inspection. All three CRLs for this combination related to manufacturing and cGMP deficiencies, not clinical data.

Why this matters

Three CRLs for the same drug in the same indication is a stark warning about manufacturing risk in biotech investing. CMC (chemistry, manufacturing, and controls) failures can kill an otherwise approvable drug regardless of how strong the clinical data is. Elevar is reviewing the letter and plans to work with the FDA on a path forward, but repeated manufacturing rejections suggest a deeper quality systems problem rather than a one-off inspection finding.

The competitive window is also closing. Standard of care in first-line HCC includes atezolizumab plus bevacizumab (Genentech/Roche), nivolumab plus ipilimumab (Bristol Myers Squibb), and durvalumab plus tremelimumab (AstraZeneca). Even if Elevar resolves the manufacturing issues on a fourth attempt, the combination would enter a crowded market years behind entrenched checkpoint inhibitor regimens. For more on what a CRL means and why manufacturing failures can kill an approvable drug, see our CRL guide.

What to watch next

Watch for Elevar’s response plan and whether a fourth resubmission is feasible. The longer-term risk is that the manufacturing site never passes inspection, which would effectively end the US approval path regardless of clinical merit. The combination remains approved and marketed in China, where Hengrui Pharma continues to generate revenue.

What It Means for the Trade

The headline for investors is the rarest kind of CRL lesson: a drug with best-in-class clinical data killed by its factory. CARES-310’s 23.8-month median overall survival against sorafenib’s 15.2 is the longest OS ever reported in first-line HCC — the efficacy case is not the problem and never was. All three CRLs cite cGMP inspection deficiencies. That pattern carries two implications. First, for Elevar/HLB specifically: three manufacturing rejections in the same program are not bad luck; they indicate a quality-systems deficit that the company either fixes at the organizational level (new facility, new CMC leadership, possibly a new manufacturing partner) or the US path stays closed permanently. Second, for the sector: CMC risk is the most underpriced failure mode in biotech — the market prices clinical binaries and competition obsessively and manufacturing not at all, right up until a 23.8-month OS asset dies at the finish line.

The competitive window compounds the manufacturing tragedy. Even a fourth-attempt approval would arrive years late into a first-line HCC market that has moved decisively to checkpoint-based doublets: atezolizumab plus bevacizumab, nivolumab plus ipilimumab, and durvalumab plus tremelimumab have all established positions, each with randomized OS data and entrenched payer coverage. A VEGFR TKI plus PD-1 combination — mechanistically credible in this landscape, as angiogenesis inhibition plus immune checkpoint release is the same logic underpinning T+A — could still have carved a niche on its OS number. But a late entrant fighting a CMC rebuild has no launch timing left.

Mechanism and Deal Context

The combination’s science deserves the respect the CRL denied it. Rivoceranib is an oral VEGFR-2 tyrosine kinase inhibitor — anti-angiogenic via the same pathway as bevacizumab’s target; camrelizumab is an anti-PD-1 antibody in the same class as Keytruda and Opdivo, with an extensive Chinese development history (studied in over 5,000 patients, eight approved indications in China). The dual mechanism — starving the tumor’s blood supply while reactivating T-cell surveillance — is the therapeutic logic that made atezo-bev the standard of care, and CARES-310’s OS result validated it with a second regimen. The discontinuation rates (17.6% camrelizumab-related, 16.9% rivoceranib-related) and grade 3+ profile (hypertension, transaminase elevations) fit the known class pattern, which is to say the tolerability was workable, not a liability.

The structural point for US-listed investors: Elevar is a majority-owned HLB (KOSDAQ) subsidiary, with the combination already approved in China as Aitan plus AiRuiKa (Hengrui’s assets). The US rejection therefore doesn’t strand the science — Chinese patients keep receiving it and Hengrui keeps its revenue — but it caps the Western commercial option at zero until the manufacturing question resolves.

Risks and What Could Go Wrong

1. The manufacturing deficiencies prove organizational rather than site-specific: a fourth rejection would close the US path definitively and probably end Elevar’s US development ambitions entirely.
2. Even a successful resubmission lands post-2027 into a market where the immunotherapy doublets have consolidated guidelines and payer formularies — the OS advantage ages into a crowded-label fight.
3. HLB’s willingness to fund a fourth attempt is not guaranteed: with lirafugratinib’s September PDUFA pending, management may triage capital toward the asset with the cleaner regulatory posture.
4. The CRL pattern itself is a valuation discount on everything Elevar files in the US going forward — the FDA will remember.

Position read: no direct US-listed trade, and the lesson is portable: this is the case study for pricing CMC risk in clinical-stage assets. When the trade is through HLB, the read is on lirafugratinib now — rivoceranib’s US option is worth its manufacturing remediation cost and nothing more.

Elevar press release | OncLive coverage